Palatin Technologies (PTN) Stock Price, Quote & News

Company Profile

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequatel...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 495 2200

Website: palatin.com

Address:

11 Deer Park Drive, Suite 204, Monmouth Junction, United States

Stocks787 Dec. 7 at 11:06 AM

$PTN Analysts at Wall Street brokerage Guggenheim have raised their price target on LLY stock to $1,163 from $1,036 previously and maintained a Buy rating on the shares. At the same time, Wolfe Research has lifted its forecast on LLY stock to $1,250 from $1,050 and reiterated a Buy-equivalent outperform rating on the shares. No limit

0 · Reply

Stocks787 Dec. 6 at 12:22 PM

$PTN With the approval of the drug, a ray of light at 100.00 good.

0 · Reply

herousa Dec. 6 at 12:14 AM

$PTN I am holding till 50 Am I crazy ?

0 · Reply

JOHNB21400 Dec. 5 at 9:48 PM

$PTN 23 HEADED TO 26

0 · Reply

DarkWatcher Dec. 5 at 8:07 PM

$AITX does any bull feels like taking out that small wall on the ask??? Maybe we have someone from $PTN that would do it… 😁😆😆😆😁 😂 how about an$AMZN bull??? Anyone??? You do it, and I’ll praise your name for weeks! 😁🤷🏻‍♂️

0 · Reply

DarkWatcher Dec. 5 at 2:46 PM

$DG $AITX $PTN go ahead… look at the charts for dg… you would see that I was right… 🤷🏻‍♂️ it dropped to 96… 😂🤷🏻‍♂️ but people said it wasn’t going to cross below105… 😂

0 · Reply

JOHNB21400 Dec. 5 at 1:40 PM

$PTN 26 and counting

0 · Reply

Rollercoaster22 Dec. 5 at 1:39 PM

$PTN

0 · Reply

foundghost Dec. 5 at 10:29 AM

$DEVS $ILLR $PTN $ANPA $BBAI

0 · Reply

Stock_Catcher Dec. 5 at 3:44 AM

Fortune Friday Watchlist Pt. 10 $ETHZ $HUBC $REPL $JFBR $PTN Let's Bank Tomorrow ✅

0 · Reply

Palatin Technologies, Inc. (PTN) Q1 2026 Earnings Call Transcript

Nov 13, 2025, 7:30 AM EST - 24 days ago

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Nov 12, 2025, 12:15 PM EST - 25 days ago

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option

Nov 6, 2025, 8:00 AM EST - 4 weeks ago

Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity

Nov 6, 2025, 7:30 AM EST - 4 weeks ago

Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering

Sep 22, 2025, 7:30 AM EDT - 2 months ago

Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim

Aug 18, 2025, 8:05 AM EDT - 3 months ago

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases

Aug 8, 2025, 4:00 PM EDT - 4 months ago

Palatin Announces 1-for-50 Reverse Stock Split

Jul 15, 2025, 7:30 AM EDT - 5 months ago

Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity

May 15, 2025, 6:43 PM EDT - 7 months ago

Palatin Technologies, Inc. (PTN) Q3 2025 Earnings Call Transcript

May 14, 2025, 7:30 AM EDT - 7 months ago

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update

May 9, 2025, 7:30 AM EDT - 7 months ago

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025

May 8, 2025, 10:19 PM EDT - 7 months ago

Palatin Technologies Announces Closing of Reduced Public Offering

May 7, 2025, 8:26 PM EDT - 7 months ago

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

May 7, 2025, 5:20 PM EDT - 7 months ago

NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)

May 7, 2025, 8:15 AM EDT - 7 months ago

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

May 7, 2025, 8:00 AM EDT - 7 months ago

Palatin Technologies Announces Pricing of up to $23 Million Public Offering

May 5, 2025, 7:30 AM EDT - 7 months ago

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

Apr 29, 2025, 7:30 AM EDT - 7 months ago

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Apr 17, 2025, 7:30 AM EDT - 8 months ago

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Apr 14, 2025, 7:00 AM EDT - 8 months ago

Palatin Appeals NYSE American Notice of Delisting

Apr 10, 2025, 4:01 PM EDT - 8 months ago

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Apr 10, 2025, 7:30 AM EDT - 8 months ago

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Mar 31, 2025, 7:30 AM EDT - 8 months ago

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Mar 28, 2025, 7:30 AM EDT - 9 months ago

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Mar 25, 2025, 7:30 AM EDT - 9 months ago

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Feb 15, 2025, 5:41 AM EST - 10 months ago

Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript

Feb 13, 2025, 7:30 AM EST - 10 months ago

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Feb 10, 2025, 4:00 PM EST - 10 months ago

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

Feb 7, 2025, 8:00 AM EST - 10 months ago

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Feb 6, 2025, 7:30 AM EST - 10 months ago

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Jan 28, 2025, 7:30 AM EST - 11 months ago

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Dec 19, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

Dec 16, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

Nov 25, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

Nov 14, 2024, 12:49 PM EST - 1 year ago

Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript

Nov 14, 2024, 7:30 AM EST - 1 year ago

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Nov 8, 2024, 9:57 AM EST - 1 year ago

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Nov 4, 2024, 7:30 AM EST - 1 year ago

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

Oct 7, 2024, 4:15 PM EDT - 1 year ago

Palatin Receives Notice of Non-Compliance from NYSE American

Oct 1, 2024, 2:55 PM EDT - 1 year ago

Palatin Technologies, Inc. (PTN) Q4 2024 Earnings Call Transcript

Oct 1, 2024, 7:30 AM EDT - 1 year ago

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Sep 26, 2024, 7:30 AM EDT - 1 year ago

Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Aug 28, 2024, 7:30 AM EDT - 1 year ago

FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)

Aug 22, 2024, 7:30 AM EDT - 1 year ago

First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds

Stocks787 Dec. 7 at 11:06 AM

0 · Reply

Stocks787 Dec. 6 at 12:22 PM

$PTN With the approval of the drug, a ray of light at 100.00 good.

0 · Reply

herousa Dec. 6 at 12:14 AM

$PTN I am holding till 50 Am I crazy ?

0 · Reply

JOHNB21400 Dec. 5 at 9:48 PM

$PTN 23 HEADED TO 26

0 · Reply

DarkWatcher Dec. 5 at 8:07 PM

0 · Reply

DarkWatcher Dec. 5 at 2:46 PM

0 · Reply

JOHNB21400 Dec. 5 at 1:40 PM

$PTN 26 and counting

0 · Reply

Rollercoaster22 Dec. 5 at 1:39 PM

$PTN

0 · Reply

foundghost Dec. 5 at 10:29 AM

$DEVS $ILLR $PTN $ANPA $BBAI

0 · Reply

Stock_Catcher Dec. 5 at 3:44 AM

Fortune Friday Watchlist Pt. 10 $ETHZ $HUBC $REPL $JFBR $PTN Let's Bank Tomorrow ✅

0 · Reply

jdlman Dec. 5 at 3:37 AM

$PTN strong buy

0 · Reply

Stock_Catcher Dec. 5 at 3:36 AM

Fortune Friday Watchlist Pt. 3 $DEVS $ILLR $PTN $ANPA $BBAI Let's Bank Tomorrow ✅

0 · Reply

DarkWatcher Dec. 4 at 9:20 PM

$AITX $PTN $GGLS I bought a stock on a run away train! https://youtu.be/NRtvqT_wMeY?si=Fg-mlJeYD5-Od_74 $DG $SQM Sometime you have to just let go and play wild!!! 😂😂😂🤘

1 · Reply

DarkWatcher Dec. 4 at 8:14 PM

$PTN $AITX $CYBL https://youtu.be/a1TOT2-1faw?si=9SP6Z_lNW5m1pVG2 🤘🤘 I’m just rocking out today!!! 🤘🤘 just wait until Trump gives everyone 2k!!! The market will go crazier than ever!!! 🤘🤘🤘

2 · Reply

DarkWatcher Dec. 4 at 8:03 PM

$PTN https://youtu.be/xPU8OAjjS4k?si=XVIWdW5yStJzCoYD lets keep the heat on them bulls!!!

1 · Reply

bbernier75 Dec. 4 at 6:37 PM

$PTN

1 · Reply

Stock_Catcher Dec. 4 at 6:17 PM

$PTN on watch off $SMX

0 · Reply

JOHNB21400 Dec. 4 at 6:15 PM

$PTN Back to target of 26

0 · Reply

Jonita Dec. 4 at 5:53 PM

$PTN 💣💣💣💣💣💣👍❤️

0 · Reply

topstockalerts Dec. 4 at 5:49 PM

$PTN here it comes… 🚨

0 · Reply

DarkWatcher Dec. 4 at 5:12 PM

$PTN https://youtu.be/w33b7sYkZkM?si=tBqVhrvf_NSCzgD3 this is a song I like to play when I’m trading… 🤷🏻‍♂️🤘🤘

0 · Reply

DarkWatcher Dec. 3 at 2:42 PM

$PTN do you dip your toe in….. or do you jump straight in??? WAKE UP!!! $CARM $VTVT

1 · Reply

Market Cap	2.45M
Revenue (ttm)	4.49M
Net Income (ttm)	-29.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-662.36%
Debt to Equity Ratio	0.00

Volume	14,571,800
Avg Vol	3,131,146
Day's Range	N/A - N/A
Shares Out	26.01M
Stochastic %K	5%
Beta	0.94
Analysts	Strong Sell
Price Target	$7.00